Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Algeta ASA, the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton.

14 Dec 2009

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

14 Dec 2009

Black women with HR-positive breast cancer have worse disease-free and overall survival, shows data

Black women with hormone receptor (HR)-positive breast cancer had worse disease-free and overall survival, according to data presented at the CTRC-AACR Annual San Antonio Breast Cancer Symposium, held Dec. 9-13, 2009.

14 Dec 2009

Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495

Ipsen today announced the preliminary results of a phase I trial in metastatic breast cancer with BN83495, Ipsen’s lead and first-in-class orally available irreversible steroid sulfatase (STS) inhibitor.

14 Dec 2009

Combination of Herceptin and chemotherapy improves treatment for women with HER2+ breast cancer

Using Herceptin with chemotherapy, instead of after, clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care, says a Mayo Clinic researcher who led what is regarded to be a key clinical trial determining the best use of Herceptin.

14 Dec 2009

Texas researchers identify new detection method for circulating tumor cells

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

Findings from three studies using bioTheranostics' breast cancer molecular test reported

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from three studies using the company's breast cancer molecular test.

14 Dec 2009

New research highlights the benefit of shortened radiation course for patients with non-invasive breast cancer

New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.

14 Dec 2009

Data from Phase 3 clinical evaluation of Lymphoseek presented

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that researchers who participated in the breast cancer arm of a Phase 3 clinical evaluation of Lymphoseek® presented data from their clinical experience at the International San Antonio Breast Cancer Symposium.

14 Dec 2009

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.

14 Dec 2009

Study examines the association of BRCA1 gene, infertility and breast/ovarian cancer

In a study published online this week in the leading cancer journal, Journal of Clinical Oncology, Westchester Medical Center Physician Dr. Kutluk Oktay, MD, Director, Division of Reproductive Medicine & Infertility concluded that mutations in the BRCA1 gene (gene associated with early onset breast cancer) are associated with early diminishment of egg reserve.

14 Dec 2009

Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics

Celldex Therapeutics, Inc. today announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers.

13 Dec 2009

ChemGenex Pharmaceuticals and Hospira enter into exclusive agreement

ChemGenex Pharmaceuticals Limited and Hospira, Inc. announced today that they have entered into an exclusive agreement to license, develop and commercialize ChemGenex’s product candidate omacetaxine mepesuccinate, a novel targeted cytotoxic pharmaceutical product, in Europe, the Middle East and parts of Africa (the Territory).

13 Dec 2009

Lapatinib plus trastuzumab extend lives of HER2-positive breast cancer patients

Lapatinib plus trastuzumab are significantly better than lapatinib alone in extending the lives of breast cancer patients whose tumors are HER2-positive, according to Kimberly Blackwell, M.D., associate professor of medicine at Duke University Medical Center.

12 Dec 2009

Results from clinical survey of Oncotype DX on patients with node-positive breast cancer announced

Genomic Health, Inc. today announced results from a clinical survey evaluating the impact of the Oncotype DX® Recurrence Score® result on physicians' adjuvant treatment recommendations for patients with node-positive, hormone receptor-positive breast cancer.

12 Dec 2009

Zevalin clinical data presented at 2009 ASH meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN (ibritumomab tiuxetan) was presented at the 51st Annual Meeting of the American Society of Hematology (ASH), which was held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

11 Dec 2009

Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics

Seattle Genetics, Inc. today reported that it has been notified by Genentech, a wholly owned member of the Roche Group, that Genentech has elected to terminate the companies’ collaboration agreement for dacetuzumab (SGN-40). Dacetuzumab is a monoclonal antibody targeting CD40 that has been investigated in clinical trials for non-Hodgkin lymphoma and multiple myeloma.

11 Dec 2009

CyMap technology wins first prize in the Medical and Healthcare category

CyMap, an innovative lens-free microscope developed by Cancer Research UK scientists and members of the Optical Biochips Consortium*, has won first prize in the Medical and Healthcare category of The Engineer's Technology and Innovation Awards as well as the overall Grand Prix prize.

11 Dec 2009

Pfizer announces IES analysis of Aromasin in breast cancer recurrence

Pfizer today announced results from an exploratory analysis of the Intergroup Exemestane Study (IES) at a median follow-up of 91 months in estrogen-receptor positive (ER+) or estrogen-receptor unknown (ER-unknown) women that looked at breast cancer free survival (BCFS) and censored deaths that occurred prior to breast cancer relapse.

11 Dec 2009

Oncology News and Research

Further Reading

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Combination therapy improves overall survival in women with advanced breast cancer

Black women with HR-positive breast cancer have worse disease-free and overall survival, shows data

Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495

Combination of Herceptin and chemotherapy improves treatment for women with HER2+ breast cancer

Texas researchers identify new detection method for circulating tumor cells

Findings from three studies using bioTheranostics' breast cancer molecular test reported

New research highlights the benefit of shortened radiation course for patients with non-invasive breast cancer

Data from Phase 3 clinical evaluation of Lymphoseek presented

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Study examines the association of BRCA1 gene, infertility and breast/ovarian cancer

Positive Phase 2 study results of CDX-011 reported by Celldex Therapeutics

ChemGenex Pharmaceuticals and Hospira enter into exclusive agreement

Lapatinib plus trastuzumab extend lives of HER2-positive breast cancer patients

Results from clinical survey of Oncotype DX on patients with node-positive breast cancer announced

Zevalin clinical data presented at 2009 ASH meeting

Genentech terminates dacetuzumab collaboration agreement with Seattle Genetics

CyMap technology wins first prize in the Medical and Healthcare category

Pfizer announces IES analysis of Aromasin in breast cancer recurrence

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News